Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2015

View Archived Issues

Inotek Pharmaceuticals begin dosing in pivotal phase III study of trabodenoson

OMT and Armo BioSciences enter into anti-PD-1 antibody agreement

Kolltan Pharmaceuticals reports efficacy data from phase Ib KTN-3379 trial

New phase IIa study investigates simeprevir, odalasvir and AL-335 treatment regimen in HCV

First clinical results presented for novel radiotracer [123/131I]IMAZA

[111In]CP04 could represent a step forward in medullary thyroid carcinoma imaging

Arisaph starts phase II trial of niacin analogue ARI-3037-MO in patients with NAFLD or NASH

HKU and international research teams identify novel PARP-1 complex

DSMB recommends continuation of phase III study of Vyxeos for AML

Luc Therapeutics licenses NMDA modulators for depression to Novartis

Fecal microbiome transplant shows favorable safety profile in HIV-infected subjects

FDA grants orphan drug designation to receptor-Fc fusion protein for the treatment of ovarian cancer

Responses seen with avelumab in trials in mesothelioma, gastric/gastroesophageal junction cancer

Novel NNT gene mutation linked to left ventricular noncompaction

First-in-human results reveal activity of SYD-985 in patients with solid tumors

Curis expands cancer drug pipeline

FDA grants orphan drug designation and fast track status to resunab for cystic fibrosis

FDA approves Coagadex for hereditary factor X deficiency

Tris Pharma's Dyanavel XR approved in U.S. for ADHD in children

Synta terminates phase III trial of ganetespib in NSCLC

InterMune discloses antifibrotic pyridinones

Taisho Pharmaceutical patents orexin receptor antagonists

Sumitomo Dainippon Pharma describes alpha7 nAChR positive allosteric modulators

Eicosis develops soluble epoxide hydrolase inhibitors

Medshine Discovery reports hedgehog signaling pathway inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...